Changing the Sentence Forever

Michael is the Chief Commercial Officer of Immix Biopharma, Inc. Michael has more than 25 years of biopharmaceutical commercialization experience. Prior to joining Immix, Michael was Head of Commercial Operations at Chimerix, Inc., where he led Go-To-Market Strategy and Launch of orphan drug MODEYSO® (dordaviprone), a first-in-disease therapy that was granted accelerated approval in 2025 for H3 K27M-mutant diffuse midline glioma, an ultra-rare and aggressive brain tumor that, prior to MODEYSO®, previously had no FDA-approved therapies. MODEYSO® was granted accelerated approval based on an integrated efficacy analysis of 50 patients, selected from five open-label studies (Jazz Pharmaceuticals acquired Chimerix for $935 million shortly after Chimerix’s New Drug Application for MODEYSO® was accepted and granted Priority Review by the FDA). Prior to Chimerix, Michael was Executive Vice President and Chief Business Officer of Spectrum Pharmaceuticals (SPPI, acquired by Assertio). Prior to Spectrum, Michael held various roles at Amgen in sales and marketing. Michael has been directly involved in driving over 10 successful commercial drug launches throughout his career. Michael holds an MBA from Pepperdine University and a BS from California State University.

Content to follow.

Mel Davis-Pickett is the Head of CMC Technical Development at Immix Biopharma, Inc. Mel possesses more than 16 years of experience in cell therapy analytical development at Bristol Myers Squibb (BMS), and the Fred Hutchison Institute. At BMS, Mel led analytical development activities for three CAR T programs, including Breyanzi®, from early phase through BLA; co-authored a FDA-approved Justification of Specification for Breyanzi ®’s Module 3, championed stability-indicating method development, and guided portfolio prioritization through cross-functional leadership, risk frameworks, and team mentorship across assay platforms. Prior, Mel was a scientist at the Fred Hutchison Cancer Research Center. Mel received a bachelor’s degree in Cell and Molecular Biology & Chemistry from the Evergreen State College.